Navigation Links
Gerresheimer Discontinues Marginal Operations
Date:6/18/2008

DUSSELDORF, Germany, June 18 /PRNewswire-FirstCall/ --

- Sale of Consumer Healthcare Business

- Concentration on Core Business of Pharmaceutics and Life Science

Gerresheimer AG, the leading manufacturer of glass and plastic products for the pharma & life science industry, is selling its consumer healthcare business. As previously announced, the Dusseldorf company is thereby discontinuing operations which are not part of the core business of pharmaceutics and life science.

"The consumer healthcare business did not fit in with our strategy of focussing on the fields of pharmaceutics and life science. In addition, because of the lack of synergies with the core business, our return requirements for the consumer healthcare business were not fulfilled," says Gerresheimer CEO Dr. Axel Herberg.

The consumer healthcare business, which comprises the production of toothbrushes and other interdental articles and most recently achieved annual sales of EUR24m, was part of the Wilden Group, which was acquired in January 2007. The purchaser is the Krallmann Group. Through the acquisition, Krallmann intends to expand its own plastic processing division and to continue the business under the traditional "Interbros" trademark. The transaction takes place with effect on 1 June 2008. The contractual parties have agreed to keep further details confidential.

Early this year, Gerresheimer already discontinued the marginal business of aluminium packaging with sales of EUR3.3m.

About Gerresheimer

Gerresheimer employs more than 10,800 people in 41 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR957.7m. The product portfolio ranges from pharma-ceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

Contact Press Contact Investor Relations

Burkhard Lingenberg Anke Linnartz

Director Corporate PR & Marketing Director Corporate Investor Relations

Telephone +49-211-6181-250 Telephone +49-211-6181-314

Telefax +49-211-6181-241 Telefax +49-211-6181-121

E-mail E-mail

b.lingenberg@gerresheimer.com a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Moodys Raises Rating for Gerresheimer
2. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
3. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
4. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
5. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
6. Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management
7. Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO
8. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
9. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
10. Medimetriks Pharmaceuticals, Inc. Begins Operations
11. Kendle Appoints Patricia Williams Vice President, Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
Breaking Biology News(10 mins):